ADC Therapeutics SA
Change company Symbol lookup
Select an option...
ADCT ADC Therapeutics SA
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp
TEAM Atlassian Corp
MRO Marathon Oil Corp
TRGP Targa Resources Corp
Go

Health Care : Biotechnology | Small Cap Value
Based in Switzerland
Company profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Price
Delayed
$2.95
Day's Change
0.075 (2.61%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.99
Day's Low
2.77
Volume
(Average)

Today's volume of 123,913 shares is on pace to be in-line with ADCT's 10-day average volume of 526,344 shares.

123,913

Display:

Providers:

UpdateCancel
6 providers
November 28, 2022
Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate...(BusinessWire)

November 08, 2022
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

--Cash runway expected into early 2025 --Company to host conference call today at 8:30 a.m. EST ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates. (BusinessWire)

November 07, 2022
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT. (BusinessWire)

November 03, 2022
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA(R) (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American...(BusinessWire)

November 02, 2022
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA(R) in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

--- Phase 1 Trial Expected to be Initiated in 1Q23 - IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they have...(BusinessWire)

November 01, 2022
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective...(BusinessWire)

October 31, 2022
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates. (BusinessWire)

September 27, 2022
September 21, 2022
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

--Cami pivotal Phase 2 data to be highlighted in encore oral and poster presentations ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA(R) (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for...(BusinessWire)

September 20, 2022
ADC Therapeutics SA Investors: Company Investigated by the Portnoy Law Firm

EQNX::TICKER_START (NYSE:ADCT), EQNX::TICKER_END Investors can contact the law firm at no cost to learn more about recovering their losses The Portnoy Law Firm advises ADC Therapeutics SA ("ADC" or "the Company") (NYSE: ADCT) investors that the firm...(Globe Newswire)

September 17, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCT

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Robert S. Willoughby at...(Newsfile)

September 16, 2022
ADC Therapeutics and Sobi Announce ZYNLONTA(R) (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi(R)) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing...(BusinessWire)

September 15, 2022
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ADC Therapeutics SA (ADCT) Investigation

NEW YORK, NY / ACCESSWIRE / September 15, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA ("ADC" or "the Company") (NYSE:ADCT). Investors who purchased ADC shares are...(Accesswire)

September 14, 2022
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 14, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofADC Therapeutics SA ("ADC" or "the Company") (NYSE:ADCT) for...(Accesswire)

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or "the Company") (NYSE: ADCT) for violations of the securities laws. (BusinessWire)

September 13, 2022
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or "the Company") (NYSE: ADCT) for violations of the securities laws. (BusinessWire)

September 12, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK, NY / ACCESSWIRE / September 12, 2022 / Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA("ADC" or the "Company") (NYSE:ADCT). Such investors are advised to contact Robert S. Willoughby at...(Accesswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.